^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
4SCAR-T
i
Other names: 4SCAR-T, 4SCAR-CD22/CD123/CD38/CD10/CD20 infusion
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
SZGIMI
Drug class:
CD20-targeted CAR-T immunotherapy, CD123-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy, CD10-targeted CAR-T immunotherapy, CD38-targeted CAR-T immunotherapy
Related drugs:
3ms
Intervention of Bladder Cancer by CAR-T (clinicaltrials.gov)
P1/2, N=20, Recruiting, Shenzhen Geno-Immune Medical Institute | Unknown status --> Recruiting | Trial completion date: Dec 2020 --> Dec 2029 | Trial primary completion date: Dec 2019 --> Dec 2028
Enrollment open • Trial completion date • Trial primary completion date
|
4SCAR-T
5years
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (clinicaltrials.gov)
P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute
Clinical • New P1/2 trial
|
CD276 (CD276 Molecule)
|
4SCAR-T
over5years
Multi-4SCAR-T Therapy Targeting Breast Cancer (clinicaltrials.gov)
P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute
New P1/2 trial • CAR T-Cell Therapy
|
HER-2 (Human epidermal growth factor receptor 2) • CD44 (CD44 Molecule)
|
HER-2 expression • CD44 expression
|
4SCAR-T
over5years
4SCAR-T Therapy Post CD19-targeted Immunotherapy (clinicaltrials.gov)
P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute
New P1/2 trial
|
CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD22 (CD22 Molecule) • MME (Membrane Metalloendopeptidase)
|
4SCAR-T
Share via
